The price-to-earnings ratio for Novo Nordisk ADR (NYSE: NVO) is above average at 43.31x. The 36-month beta value for NVO is also noteworthy at 0.44. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for NVO is 3.34B, and at present, short sellers hold a 0.09% of that float. The average trading volume of NVO on August 05, 2024 was 3.81M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
NVO) stock’s latest price update
Novo Nordisk ADR (NYSE: NVO) has seen a decline in its stock price by -1.62 in relation to its previous close of 127.49. However, the company has experienced a -2.05% decline in its stock price over the last five trading sessions. reuters.com reported 2024-08-05 that As Eli Lilly’s weight-loss drug Zepbound gains ground in the U.S. against Novo Nordisk’s Wegovy, some doctors say their guiding principle for writing prescriptions is simple: which drug can my patients actually get at the pharmacy?
NVO’s Market Performance
Novo Nordisk ADR (NVO) has seen a -2.05% fall in stock performance for the week, with a -11.90% decline in the past month and a 1.93% surge in the past quarter. The volatility ratio for the week is 2.18%, and the volatility levels for the past 30 days are at 2.02% for NVO. The simple moving average for the past 20 days is -6.74% for NVO’s stock, with a 4.26% simple moving average for the past 200 days.
Analysts’ Opinion of NVO
Many brokerage firms have already submitted their reports for NVO stocks, with Goldman repeating the rating for NVO by listing it as a “Buy.” The predicted price for NVO in the upcoming period, according to Goldman is $156 based on the research report published on May 30, 2024 of the current year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see NVO reach a price target of $163. The rating they have provided for NVO stocks is “Outperform” according to the report published on April 12th, 2024.
Morgan Stanley gave a rating of “Overweight” to NVO, setting the target price at $120 in the report published on January 23rd of the current year.
NVO Trading at -9.10% from the 50-Day Moving Average
After a stumble in the market that brought NVO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.34% of loss for the given period.
Volatility was left at 2.02%, however, over the last 30 days, the volatility rate increased by 2.18%, as shares sank -12.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.11% lower at present.
During the last 5 trading sessions, NVO fell by -2.77%, which changed the moving average for the period of 200-days by +23.07% in comparison to the 20-day moving average, which settled at $133.56. In addition, Novo Nordisk ADR saw 21.25% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for NVO
Current profitability levels for the company are sitting at:
- 0.45 for the present operating margin
- 0.85 for the gross margin
The net margin for Novo Nordisk ADR stands at 0.37. The total capital return value is set at 0.82. Equity return is now at value 99.99, with 32.56 for asset returns.
Based on Novo Nordisk ADR (NVO), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at 3.47. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is 45.41.
Currently, EBITDA for the company is 112.94 billion with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 15.38. The receivables turnover for the company is 3.87for trailing twelve months and the total asset turnover is 0.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.70.
Conclusion
In summary, Novo Nordisk ADR (NVO) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
